Below is from an investor presentation ppt of a similar listed biotech company.
“REGULATORY
– Materials that are going to be given to humans as potential treatments need to meet certainstandards set by government regulatory agencies
– The process for manufacturing biologics defines the final product
– The pathway for the development of biologics manufacturing takes 12-18 months – sometimeslonger
SAFETY
– A defined process is required to produce biologics materials in order to begin clinical trials inhumans
CREATING A COMMERCIAL PRODUCT
– Investing time in manufacturing is critical for the success of a biologics program
– The manufacturing process forms an integral part of a due diligence package for the potentialpartnering of a biologics product”
In PAB case, according to the latest corporate overview, the development of DX1 manufacturing (incl cell line development and expression, purification and formulation) is expected to take about 16 months till Q2 2020. Logically and as is common practice, only with the manufacturing process in place can T/O due diligence occurs. Apparently, there is still long way to go. But anyway, the rise of Patrys is just a matter of time so stay confident and let time work for us.
Below is from an investor presentation ppt of a similar listed...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $3.399K | 485.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 3120846 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 218873 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |